Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
- Conditions
- BPHLUTSBenign Prostatic HyperplasiaLower Urinary Tract Symptoms (LUTS)
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT01846793
- Locations
- πΊπΈ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Dallas, Texas, United States
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 141
- Registration Number
- NCT01620515
- Locations
- πΊπΈ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Salt Lake City, Utah, United States
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 192
- Registration Number
- NCT01438775
- Locations
- πΊπΈ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Houston, Texas, United States
πΊπΈFor information concerning this clinical site, please contact Nymox at 800-936-9669, San Antonio, Texas, United States
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00945490
- Locations
- πΊπΈ
For information concerning this clinical site, please contact Nymox at 800-936-9669., Richmond, Virginia, United States
πΊπΈFor information concerning this clinical site, please contact Nymox at 800-936-9669, Grand Rapids, Michigan, United States
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Nymox Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT00918983
- Locations
- πΊπΈ
For information concerning this clinical site, please contact Nymox at 800-936-9669, Bala Cynwyd, Pennsylvania, United States
πΊπΈFor information concerning this clinical site, please contact Nymox at 800-936-9669., Salt Lake City, Utah, United States
- Prev
- 1
- 2
- Next